Nihon Kohden (Japan) defibrillators cleared for US:
This article was originally published in Clinica
Nihon Kohden's (Japan) Cardiolife defibrillators have been removed from import detention by the US FDA. A GMP inspection of the company's manufacturing plant in Kawamoto, Japan, confirmed that Nihon Koden has corrected the outstanding production issue related to the devices. Resumption of exports to the US has been cleared by the FDA.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.